Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Publisher Name :
Date: 15-Dec-2013
No. of pages: 89

GBI Research, has released the pharma report “Monoclonal Antibodies Market in Colorectal Cancer to 2019 Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications. While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment. Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. As a result of this, GBI Research believes the global market has the potential to grow to a value of $5.5 billion by 2019.

Scope

  • A brief introduction to colorectal cancer, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms.
  • In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy.
  • A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints.
  • Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets.
  • Discussion of the drivers and barriers for market growth.
  • In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006.

Reasons to buy

  • Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies.
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
  • Observe the trends in clinical trial duration and size amongst clinical phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for colorectal cancer therapeutics.
  • Observe the shift in clinical trial endpoints throughout clinical phases of development, and use this data to potentially influence any future developmental programs.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the colorectal cancer mAbs market.

Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Introduction 9
2.1 Symptoms 9
2.2 Etiology 9
2.3 Epidemiology 10
2.4 Pathophysiology 11
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 12
2.7 Treatment Options 13
2.7.1 Chemotherapy 13
2.7.2 Targeted Therapies 14
2.7.3 Resistance to Pharmacological Therapies 15
2.7.4 Treatment Guidelines 15

3 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Marketed Products 18
3.1 Avastin (Bevacizumab) - Hoffman La Roche 18
3.2 Erbitux (Cetuximab) - Bristol-Myers Squibb, Eli Lilly, and Merck KGaA 19
3.3 Vectibix (Panitumumab) - Amgen and Takeda 21
3.4 Heat Map for Marketed Products 22
3.5 Conclusion 24

4 Monoclonal Antibodies in Colorectal Cancer Market to 2019 - Developmental Pipeline 25
4.1 Overall Pipeline 25
4.2 Molecular Targets and Mechanisms of Action 27
4.3 Clinical Trials 28
4.3.1 Failure Rate 28
4.3.2 Clinical Trial Size 29
4.3.3 Duration 32
4.3.4 Primary Endpoints 33
4.4 Conclusion 35
4.5 Key Late-Stage Pipeline Products 35
4.5.1 IMC-1121B (Ramucirumab) - Eli Lilly and Company 35
4.5.2 Xilonix - XBiotech 36
4.5.3 MetMAb (Onartuzumab) - Hoffmann-La Roche 36
4.5.4 Anti-DR5 MoAb (Tigatuzumab) - Daiichi Sankyo 36
4.5.5 MK0646 (Dalotuzumab) - Merck 37
4.5.6 AMG-655 (Conatumumab) - Amgen 37
4.6 Conclusion 37

5 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Market Forecast to 2019 38
5.1 Global 39
5.1.1 Treatment Usage Patterns 39
5.1.2 Market Size 40
5.2 North America 41
5.2.1 US 41
5.2.2 Canada 43
5.3 Europe 44
5.3.1 Treatment Usage Patterns 44
5.3.2 Annual Cost of Therapy 45
5.3.3 Market Size 47
5.4 Japan 48
5.4.1 Treatment Usage Patterns 48
5.4.2 Market Size 49
5.5 Drivers and Barriers 49
5.5.1 Drivers 49
5.5.2 Barriers 50

6 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Deals and Strategic Consolidations 52
6.1 R&D Licensing Agreements 52
6.1.1 Key Licensing Deals 55
6.2 Co-Development Agreements 57
6.2.1 Key Co-Development Agreements 58

7 Monoclonal Antibodies in Colorectal Cancer Market to 2019- Appendix 59
7.1 Market Definitions 59
7.2 Abbreviations 59
7.3 References 62
7.4 Sources for Heat Map 66
7.5 All Pipeline Products, by Stage of Development 67
7.5.1 Discovery 67
7.5.2 Preclinical and IND/CTA-filed 68
7.5.3 Phase I 73
7.5.4 Phase II 76
7.5.5 Phase III and Pre-registration 81
7.5.6 Undisclosed 82
7.6 Tabular Forecast Data 83
7.6.1 Global 83
7.6.2 US 83
7.6.3 Canada 83
7.6.4 UK 83
7.6.5 France 84
7.6.6 Germany 84
7.6.7 Italy 84
7.6.8 Spain 84
7.6.9 Japan 85
7.7 Research Methodology 85
7.7.1 Coverage 85
7.7.2 Secondary Research 85
7.7.3 Primary Research 86
7.7.4 Therapeutic Landscape 86
7.7.5 Epidemiology-Based Forecasting 86
7.7.6 Market Size by Geography 88
7.7.7 Geographical Landscape 89
7.7.8 Pipeline Analysis 89
7.8 Contact Us 89
7.9 Disclaimer 89

List of Tables

Table 1: Market for mAbs in Colorectal Cancer, US, Epidemiology, 2008 10
Table 2: Market for mAbs in Colorectal Cancer, US, Diagnosis by Stage, 2009 10
Table 3: Market for mAbs in Colorectal Cancer, US, Five-Year Survival by Stage, 2009 12
Table 4: Market for mAbs in Colorectal Cancer, Global, TNM Staging, 2013 13
Table 5: Market for mAbs in Colorectal Cancer, Sources for Heat Map 66
Table 6: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 67
Table 7: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013 68
Table 8: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013 73
Table 9: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 76
Table 10: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 81
Table 11: Colorectal Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013 82
Table 12: Market for mAbs in Colorectal Cancer, Global, Forecast Data, 2012-2019 83
Table 13: Market for mAbs in Colorectal Cancer, US, Forecast Data, 2012-2019 83
Table 14: Market for mAbs in Colorectal Cancer, Canada, Forecast Data, 2012-2019 83
Table 15: Market for mAbs in Colorectal Cancer, UK, Forecast Data, 2012-2019 83
Table 16: Market for mAbs in Colorectal Cancer, France, Forecast Data, 2012-2019 84
Table 17: Market for mAbs in Colorectal Cancer, Germany, Forecast Data, 2012-2019 84
Table 18: Market for mAbs in Colorectal Cancer, Italy, Forecast Data, 2012-2019 84
Table 19: Market for mAbs in Colorectal Cancer, Spain, Forecast Data, 2012-2019 84
Table 20: Market for mAbs in Colorectal Cancer, Japan, Forecast Data, 2012-2019 85

List of Figures

Figure 1: Market for mAbs in Colorectal Cancer, Global, ESMO Treatment Guidelines (Colorectal Cancer at Stage I to III) 16
Figure 2: Market for mAbs in Colorectal Cancer, Global, ESMO Treatment Guidelines (Colorectal Cancer at Stage IV) 17
Figure 3: Market for mAbs in Colorectal Cancer, Global, Sales of Avastin ($bn), 2004-2012 19
Figure 4: Market for mAbs in Colorectal Cancer, Global, Sales of Vectibix ($m), 2006-2012 21
Figure 5: Market for mAbs in Colorectal Cancer, Global, Heat Map of Safety and Efficacy for Marketed Products, 2013 23
Figure 6: Market for mAbs in Colorectal Cancer, Global, Overall Pipeline, 2013 26
Figure 7: Market for mAbs in Colorectal Cancer, Global, Pipeline mAbs by Mechanism of Action and Molecular Target, 2013 27
Figure 8: Market for mAbs in Colorectal Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013 28
Figure 9: Market for mAbs in Colorectal Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013 29
Figure 10: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Sizes, 2006-2013 30
Figure 11: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013 31
Figure 12: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Durations, 2006-2013 32
Figure 13: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013 33
Figure 14: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Primary Endpoints, 2006-2012 34
Figure 15: Market for mAbs in Colorectal Cancer, Global, Clinical Trial Primary Endpoints, 2006-2012 35
Figure 16: Market for mAbs in Colorectal Cancer, Global, Market Growth and Size, 2012-2019 38
Figure 17: Market for mAbs in Colorectal Cancer, Global, Treatment Patterns, 2012-2019 39
Figure 18: Market for mAbs in Colorectal Cancer, Global, Market Size ($bn), 2012-2019 40
Figure 19: Market for mAbs in Colorectal Cancer, US, Treatment Usage Patterns, 2012-2019 41
Figure 20: Market for mAbs in Colorectal Cancer, US, Market Size ($m), 2012-2019 42
Figure 21: Market for mAbs in Colorectal Cancer, Canada, Treatment Usage Patterns, 2012-2019 43
Figure 22: Market for mAbs in Colorectal Cancer, Canada, Market Size ($m), 2012-2019 44
Figure 23: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Treatment Patterns, 2012-2019 45
Figure 24: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Annual Cost of Therapy, 2012-2019 46
Figure 25: Market for mAbs in Colorectal Cancer, Leading Five European Markets, Market Size ($m), 2012-2019 47
Figure 26: Market for mAbs in Colorectal Cancer, Japan, Treatment Usage Patterns, 2012-2019 48
Figure 27: Market for mAbs in Colorectal Cancer, Japan, Market Size ($m), 2012-2019 49
Figure 28: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 52
Figure 29: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 53
Figure 30: Market for mAbs in Colorectal Cancer, Global, Licensing Deals (All Molecule Types), 2006-2012 54
Figure 31: Market for mAbs in Colorectal Cancer, Global, Co-development Deals Global Network, 2006-2013 57
Figure 32: Market for mAbs in Colorectal Cancer, Global, Co-development Deals by Year and Value, 2006-2013 58
Figure 33: GBI Research Market Forecasting Model 88

  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Antibody Deals and Alliances of 2013
    Published: 1-Aug-2014        Price: US $1495 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." The Antibody Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced wo......
  • Research on China Monoclonal Antibody (McAB) Industry, 2014
    Published: 1-Jul-2014        Price: US $2000 Onwards        Pages: 60
    "Please Note: The report is in Chinese version now. The English version will be delivered in 1-2 business days." Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on policy environment, global market, Chinese market, as well as the latest developments of domestic key enterprises related to China's monoclonal antibody industry. Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and development of monoclonal ant......
  • Global and China Monoclonal Antibody Industry Report, 2013-2017
    Published: 23-Dec-2013        Price: US $2500 Onwards        Pages: 118
    Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period. Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal......
  • Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
    Published: 15-Dec-2013        Price: US $3500 Onwards        Pages: 106
    GBI Research has released the pharma report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment option......
  • Patrys Limited – Product Pipeline Review – 2013
    Published: 30-Sep-2013        Price: US $1500 Onwards        Pages: 49
    Global Market Direct's pharmaceuticals report, "Patrys Limited Product Pipeline Review 2013" provides data on the Patrys Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Patrys Limited's corporate website, SEC filings, investor presentations and fe......
  • Research Report on Global and China Monoclonal Antibody Industry, 2013-2017
    Published: 2-Aug-2013        Price: US $2200 Onwards        Pages: 50
    Antibody drugs are usually generated from monoclonal antibody through genetic engineering, with the advantages of strong targeting, few side effects, etc. With rather promising application prospect in clinic treatment, antibody drugs are mainly applied in curing diseases like tumour, immune system and so on. In terms of the global market, antibody drugs account for over 40% of the entire biotech drug market and the market share still keeps increasing. Antibody drugs have become one of the most i......
  • Monoclonal Antibody Markets in China
    Published: 1-May-2013        Price: US $4000 Onwards        Pages: 187
    China's demand for monoclonal antibody has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.......
  • Synagis (Pediatric RSV) – Forecast and Market Analysis to 2022
    Published: 30-Apr-2013        Price: US $3495 Onwards        Pages: 48
    GlobalData has released its new PharmaPoint Drug Evaluation report, “Synagis (Pediatric RSV) Forecast and Market Analysis to 2022”. Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person’s sneeze or cough, or through direct and indirect contac......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs